AI Engines For more Details: Perplexity Kagi Labs You
Antibacterial Activity: Hexetidine exhibits broad-spectrum antibacterial activity against various Gram-positive and Gram-negative bacteria, as well as fungi and some viruses. It works by disrupting the cell membrane integrity of microorganisms, leading to their death.
Oral Hygiene: Hexetidine is widely used in mouthwashes and gargles for the prevention and treatment of oral infections, including gingivitis, stomatitis, and pharyngitis. It helps reduce plaque formation, control bad breath (halitosis), and promote overall oral hygiene.
Sore Throat Relief: Hexetidine-containing throat sprays or gargles are effective in providing temporary relief from sore throat symptoms, such as pain, irritation, and inflammation.
Topical Antiseptic: Hexetidine solutions or sprays are also used topically for wound cleansing and as an antiseptic for minor cuts, abrasions, and skin infections. It helps prevent bacterial growth and promotes wound healing.
Fungal Infections: Hexetidine has antifungal properties and can be used in the treatment of fungal infections of the mouth and throat, such as oral thrush (oral candidiasis) caused by Candida albicans.
Vaginal Infections: In gynecology, hexetidine is sometimes used as a vaginal douche or wash for the treatment of vaginal infections, including bacterial vaginosis and vaginal candidiasis.
Mode of Action: Hexetidine acts by disrupting the cell membrane of microorganisms, leading to leakage of cellular contents and ultimately cell death. It also inhibits the adherence of bacteria to oral surfaces, thereby reducing plaque formation and preventing infection.
Safety: Hexetidine is generally well-tolerated when used as directed. However, some individuals may experience minor side effects such as temporary taste disturbances, mild irritation, or allergic reactions. It is important to follow the recommended dosage and usage instructions provided by healthcare professionals.
Pregnancy and Lactation: The safety of hexetidine use during pregnancy and breastfeeding has not been fully established. Pregnant or lactating individuals should consult healthcare professionals before using products containing hexetidine.
Drug Interactions: There are no known significant drug interactions with hexetidine. However, it is advisable to inform healthcare providers about all medications and supplements being taken to avoid potential interactions.
| Rank | Probiotic | Impact |
|---|---|---|
| species | Lacticaseibacillus paracasei | Reduces |
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species, that would be the genus that is belongs to and the strains in the species.
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups. We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
| Condition | Positive Impact | Negative Impact | Benefit Ratio Impact |
|---|---|---|---|
| Abdominal Aortic Aneurysm | 0.4 | 0.4 | |
| ADHD | 1.4 | 0.5 | 1.8 |
| Age-Related Macular Degeneration and Glaucoma | 1 | 0.1 | 9 |
| Allergic Rhinitis (Hay Fever) | 1.5 | 1.5 | |
| Allergies | 2.4 | 1.7 | 0.41 |
| Allergy to milk products | 0.7 | 0.1 | 6 |
| Alopecia (Hair Loss) | 1.3 | 1.3 | |
| Alzheimer's disease | 2.1 | 6.3 | -2 |
| Amyotrophic lateral sclerosis (ALS) Motor Neuron | 2.3 | 0.3 | 6.67 |
| Ankylosing spondylitis | 2.1 | 1.9 | 0.11 |
| Anorexia Nervosa | 0.1 | 2.7 | -26 |
| Antiphospholipid syndrome (APS) | 1.2 | 0.4 | 2 |
| Asthma | 0.3 | 0.6 | -1 |
| Atherosclerosis | 0.3 | 1.8 | -5 |
| Atrial fibrillation | 3.1 | 1.4 | 1.21 |
| Autism | 6 | 6.9 | -0.15 |
| Barrett esophagus cancer | 0.1 | -0.1 | |
| Bipolar Disorder | 0.9 | 1.3 | -0.44 |
| Brain Trauma | 0.6 | -0.6 | |
| Carcinoma | 2 | 1.6 | 0.25 |
| Celiac Disease | 0.2 | 2.4 | -11 |
| Cerebral Palsy | 0.3 | 1.4 | -3.67 |
| Chronic Fatigue Syndrome | 2.6 | 4.4 | -0.69 |
| Chronic Kidney Disease | 2.2 | 2.5 | -0.14 |
| Chronic Lyme | 0.6 | -0.6 | |
| Chronic Obstructive Pulmonary Disease (COPD) | 0.2 | 1.5 | -6.5 |
| Chronic Urticaria (Hives) | 0.3 | 1.1 | -2.67 |
| Coagulation / Micro clot triggering bacteria | 0.2 | 1.4 | -6 |
| Colorectal Cancer | 1.6 | 0.5 | 2.2 |
| Constipation | 0.6 | 1 | -0.67 |
| Coronary artery disease | 1.8 | 1 | 0.8 |
| COVID-19 | 4.2 | 10.3 | -1.45 |
| Crohn's Disease | 4.5 | 5.4 | -0.2 |
| cystic fibrosis | 0.6 | -0.6 | |
| deep vein thrombosis | 0.9 | -0.9 | |
| Depression | 4.2 | 5.8 | -0.38 |
| Dermatomyositis | 0.1 | 0.1 | |
| Eczema | 1 | 0.8 | 0.25 |
| Endometriosis | 1.8 | 0.8 | 1.25 |
| Epilepsy | 1 | 0.7 | 0.43 |
| Fibromyalgia | 2.6 | 2.2 | 0.18 |
| Functional constipation / chronic idiopathic constipation | 2.7 | 3.5 | -0.3 |
| gallstone disease (gsd) | 1.7 | 0.5 | 2.4 |
| Gastroesophageal reflux disease (Gerd) including Barrett's esophagus | 0.4 | 1.1 | -1.75 |
| Generalized anxiety disorder | 1.5 | 0.9 | 0.67 |
| giant cell arteritis | 0.3 | -0.3 | |
| Glioblastoma | 0.1 | -0.1 | |
| Gout | 0.5 | -0.5 | |
| Graves' disease | 0.2 | 1.5 | -6.5 |
| Halitosis | 0.1 | 0.1 | 0 |
| Hashimoto's thyroiditis | 2.6 | 0.5 | 4.2 |
| Hidradenitis Suppurativa | 0.4 | 0.4 | |
| Histamine Issues,Mast Cell Issue, DAO Insufficiency | 1.6 | 1.5 | 0.07 |
| hypercholesterolemia (High Cholesterol) | 0.3 | 0.3 | |
| hyperglycemia | 0.7 | -0.7 | |
| hypersomnia | 0.9 | -0.9 | |
| hypertension (High Blood Pressure | 0.6 | 2.4 | -3 |
| Hypothyroidism | 1 | -1 | |
| Hypoxia | 0.2 | 0.2 | |
| IgA nephropathy (IgAN) | 3.1 | -3.1 | |
| Inflammatory Bowel Disease | 2.3 | 7.2 | -2.13 |
| Insomnia | 0.7 | 1.1 | -0.57 |
| Intelligence | 0.8 | 0.8 | 0 |
| Intracranial aneurysms | 1.1 | 1.1 | |
| Irritable Bowel Syndrome | 1.3 | 1.2 | 0.08 |
| Liver Cirrhosis | 3.3 | 2.6 | 0.27 |
| Long COVID | 4.8 | 6.6 | -0.38 |
| Low bone mineral density | 1.5 | -1.5 | |
| Lung Cancer | 1.3 | -1.3 | |
| ME/CFS with IBS | 0.6 | 3.1 | -4.17 |
| ME/CFS without IBS | 1.5 | 1.9 | -0.27 |
| Metabolic Syndrome | 4.6 | 3.6 | 0.28 |
| Mood Disorders | 5.9 | 5.8 | 0.02 |
| multiple chemical sensitivity [MCS] | 0.2 | 0.5 | -1.5 |
| Multiple Sclerosis | 2 | 5.4 | -1.7 |
| Multiple system atrophy (MSA) | 0.8 | -0.8 | |
| Neuropathy (all types) | 0.6 | 0.6 | |
| Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic | 2.1 | 3.9 | -0.86 |
| Obesity | 6.2 | 3.1 | 1 |
| obsessive-compulsive disorder | 2.8 | 4.9 | -0.75 |
| Osteoarthritis | 2.1 | 0.3 | 6 |
| Osteoporosis | 0.7 | 0.6 | 0.17 |
| pancreatic cancer | 0.1 | 0.1 | |
| Parkinson's Disease | 1.1 | 4.2 | -2.82 |
| Polycystic ovary syndrome | 1.3 | 1.4 | -0.08 |
| Postural orthostatic tachycardia syndrome | 0.3 | 0.5 | -0.67 |
| Premenstrual dysphoric disorder | 0.5 | 0.1 | 4 |
| primary biliary cholangitis | 0.5 | 0.5 | |
| Psoriasis | 2.5 | 2.3 | 0.09 |
| rheumatoid arthritis (RA),Spondyloarthritis (SpA) | 5.3 | 2.2 | 1.41 |
| Rosacea | 1.3 | 0.8 | 0.63 |
| Schizophrenia | 2.7 | 2.1 | 0.29 |
| scoliosis | 0.5 | 1.7 | -2.4 |
| Sjögren syndrome | 1.5 | 1.7 | -0.13 |
| Sleep Apnea | 1.3 | 1.6 | -0.23 |
| Small Intestinal Bacterial Overgrowth (SIBO) | 0.1 | 0.1 | |
| Stress / posttraumatic stress disorder | 1.5 | 1.1 | 0.36 |
| Systemic Lupus Erythematosus | 3 | 1.8 | 0.67 |
| Tic Disorder | 0.3 | 1.3 | -3.33 |
| Tourette syndrome | 0.1 | -0.1 | |
| Type 1 Diabetes | 2.1 | 1.3 | 0.62 |
| Type 2 Diabetes | 4.3 | 3.3 | 0.3 |
| Ulcerative colitis | 1.9 | 2.7 | -0.42 |
| Unhealthy Ageing | 3.6 | 2 | 0.8 |
This is an Academic site. It generates theoretical models of what may benefit a specific microbiome results.
Explanations/Info/Descriptions are influenced by Large Language Models and may not be accurate and include some hallucinations. Please report any to us for correction.
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 § 1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.